Oxidative stress increases A1 adenosine receptor expression by activating nuclear factor κB

Molecular Pharmacology

Volumn 53, Issue 4, 1998, Pages 663-669

  Nie, Zhongzhen ^a   Mei, Yun ^a   Ford, Mary ^a   Rybak, Leonard ^a   Marcuzzi, Adrianna ^a   Ren, Hongzu ^b   Stiles, Gary L ^b   Ramkumar, Vickram ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE DERIVATIVE; CATALASE; CISPLATIN; DEXAMETHASONE; GENISTEIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; IMMUNOBLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SCAVENGING SYSTEM; SMOOTH MUSCLE FIBER;

EID: 0031958046     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.4.663     Document Type: Article

References (30)

1. Babbit DG, Virmani R, and Foreman MB (1989) Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 80:1388-1399.
2. Baeuerle PA (1991) The inducible transcription activator NFκB: regulation by distinct protein subunits. Biochim Biophys Acta 1072:63-80.
3. Baeuerle PA and Baltimore D (1996). NFκB: ten years later. Cell 87:13-20.
4. Beg AA and Baltimore D (1997) An essential role for NFκB in preventing TNF-α-induced cell death. Science (Washington, DC) 274:782-784.
5. Berlin V and Haseltine WA (1981). Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem 256:4747-4756.
6. Berne RM and Rubio R (1974). Adenine nucleotide metabolism in the heart. Circ Res 35(S3):109-120.
7. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254.
8. DeLean A, Hancock AA, and Lefkowitz RJ (1982). Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21:5-16.
9. Ford M, Nie Z, Whitworth C, Rybak LP, and Ramkumar V (1997) Up-regulation of adenosine receptors in the cochlea by cisplatin. Hear Res 111:143-152.
10. Hancock A, DeLean A, and Lefkowitz RJ (1979) Quantitative resolution of β-adrenergic receptor subtypes by selective ligand binding: application of a computerized model fitting technique. MoIlPharmacol 16:1-9.
11. Lee KS, Tetzlaff T, and Kreutzberg GW (1986) Rapid down regulation of hippocampal adenosine receptors following brief anoxia. Brain Res 380:155-158.
12. 1 adenosine receptors in rabbit heart. Circulation 84:350-356.
13. Macias JF, Fiksten-Olsen M, Romero JC, and King FG (1983) Intrarenal blood flow distribution during adosine-mediated vasoconstriction. Am J Physiol 244:H138-H141.
14. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, and Matsushima T (1994) Novel mechanism of glucocorticoid-mediated gene repression. J Biol Chem 269:13289-13295.
15. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, and Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (Washington, DC) 197:165-167.
16. Ohkawa H, Ohishi N, and Yagi K (1978) Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J Lipid Res 19:1053-1057.
17. Powis G (1991) Toxicity of free radical-forming anticancer drugs, in The Toxicology of Anticancer Drugs (Powis G and Hacker MP, eds) pp 106-151, Pergamon Press, New York.
18. Quandt K, Frech K, Karas H, Wingender E, and Werner T (1995) MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23:4878-4884.
19. 1MF-2 cells. Mol Pharmacol 40:639-647.
20. Ravi R, Somani SM, and Rybak LP (1995) Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76:386-394.
21. 1 adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance. Mol Pharmacol 48:975-980.
22. 1) receptors by caffeine treatment. Neurosci Lett 103:275-280
23. Rudoiphi KA, Schubert P, Parkinson FE, and Fredholm BB (1992) Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13:439-445.
24. Rybak LP, Ravi R, and Somani SM (1995) Mechanism of protection by diethyldithio-carbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 26:293-300.
25. Sasada T, Iwata S, Sato N, Kitacoka Y, Hirota K, Nakamura K, Nishiyama K, Taniguchi Y, Takabayashi A, and Yodoi J (1996) Redox control of resistance to cisdiamminedichloroplatinum (II) (CDDP). Protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97:2268-2276.
26. Sen R and Baltimore D (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-71
27. Sun S-C, Maggirwar SB, and Harhaj E (1995) Activation of NFκB by phosphatase inhibitors involves the phosphorylation of IκBα at phosphatase 2A-sensitive sites. J Biol Chem 270:18347-18351.
28. Von Lubitz DKJE, Lin RCS, Melman N, Ji X-D, Carter MF, and Jacobson KA (1994) Chronic administration of selective adenosine A, receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol 256:161-167.
29. Wang C-Y, Mayo MW, and Baldwin AS Jr (1997) TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFκB. Science Washington, (DC) 274:784-787.
30. Wingender E, Kel AE, Kel OV, Karas H, Heinemeyer T, Dietze P, Knueppel R, Romaschenko AG, and Kolchanov NA (1997). TRANSFAC, TRRD and COMPEL: towards a federated database system on transcriptional regulation. Nucleic Acids Res 25:265-268.